By filing a prospectus supplement to increase the offering price of its common stock, Allarity Therapeutics is signaling its intent to raise additional capital. This move could be seen positively by investors as it indicates the company's proactive approach to funding its operations and growth, potentially leading to a short-term positive impact on its stock price.